EURONEXT-AMS$PHAR
Pharming Group NV · Q2 2026 earnings
Q2 2026 earnings · · Investor relations
Briefing
Pharming Group NV reported Q2 2026 total revenues of $90.2 million, down 3% year-over-year, with net profit of $1.6 million.
Pharming Group NV delivered Q2 2026 revenues of $90.2 million, a 3% decline from the prior year, driven by a 10% drop in RUCONEST offset by 40% growth in Joenja. Operating profit was $1.3 million and net profit reached $1.6 million. The company revised full-year 2026 revenue guidance downward to $375-395 million while improving operating expense guidance.
- Total revenues $90.2M (-3% YoY); RUCONEST $72.3M (-10%), Joenja $17.9M (+40%)
- Operating profit $1.3M and net profit $1.6M; adjusted operating profit $7.9M
- 132 APDS patients on paid Joenja therapy in the US (+16% YoY); cash position $159.5M
- 2026 revenue guidance lowered to $375-395M; opex guidance improved to $315-320M
Headline financials
Revenue & EPS history
Pharming Group NV · Revenue · Quarterly
$90.2M
Revenue by segment
Pharming Group NV · $90.2M total across 4 segments · Q2 2026
- RUCONEST US$72M—79.8%
- Joenja US$15.4M—17.1%
- Joenja EU & RoW$2.5M—2.8%
- RUCONEST EU & RoW$300K—0.3%
Forward guidance
Updated 2026 total revenue guidance to $375-395 million (0-5% growth) and operating expenses to $315-320 million.
Tailwinds
- Strong Joenja momentum with 40% revenue growth and geographic expansion
- RUCONEST patient base resilient at 93% of prior year with new enrollments increasing
- Improved operating expense guidance reflecting disciplined cost management
Headwinds
- Lowered full-year revenue guidance by $30 million due to market dynamics
- Q2 operating profit impacted by inventory impairments and site closure costs
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
38%
6 / 16 earnings
Positive
+12.5%
Q2 2022
Best reaction
-26.8%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2026 | -26.8% | -93.2% | -93.1% | |
| Q3 2025 | +11.5% | +19.8% | +27.1% | |
| Q2 2024 | -8.4% | -2.9% | -7.7% | |
| Q1 2024 | -1.7% | -3.3% | -12.6% | |
| Q4 2023 | -1.7% | -1.0% | -5.2% | |
| Q3 2023 | +5.0% | +14.0% | +12.0% | |
| Q2 2023 | +4.2% | -0.5% | -1.4% | |
| Q1 2023 | -20.4% | -7.7% | -4.8% | |
| Q4 2022 | -1.6% | -14.2% | -6.2% | |
| Q3 2022 | +0.0% | +24.3% | +28.2% | |
| Q2 2022 | +12.5% | +29.6% | +59.2% | |
| Q1 2022 | +3.8% | +7.7% | +7.9% | |
| Q4 2021 | +1.3% | -2.7% | +5.8% | |
| Q3 2021 | -12.6% | -7.5% | -13.6% | |
| Q2 2021 | -6.8% | -8.8% | -4.0% | |
| Q1 2021 | -8.4% | -6.9% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro